Anti-STEAP2 Bispecific Antibodies for Targeted T Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches lack effective methods for specifically targeting and killing STEAP2-expressing cells, such as prostate cancer cells, and for stimulating T cell activation against these cells.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to STEAP2 and CD3, including antibody-drug conjugates and bispecific antibodies, which facilitate targeted killing of STEAP2-expressing cells and stimulate T cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional therapeutic approaches are used, then general cancer treatment is provided, but specific targeting of STEAP2-expressing cells is lacking
Solution Approach 1:
The patent introduces anti-STEAP2 antibodies as intermediary molecules that specifically bind to STEAP2-expressing cells, enabling precise targeting. These antibodies serve as mediators between the therapeutic agent and the target cells, providing both specificity and versatility through different antibody formats (monoclonal, bispecific, ADCs)
Solution Approach 2:
The patent employs multiple antibody formats (monoclonal antibodies, bispecific antibodies, antibody-drug conjugates) that can all target STEAP2, providing universal applicability across different therapeutic strategies while maintaining specific targeting capability
2Reliability
If T cell activation is stimulated against STEAP2-expressing cells, then immune response is enhanced, but effective killing mechanism is required
Solution Approach 1:
The patent utilizes the body's own T cells to kill STEAP2-expressing cells. The anti-STEAP2 antibodies or bispecific antibodies enable T cells to autonomously recognize and eliminate target cells through natural immune mechanisms, making the system self-service and reducing the need for external killing mechanisms
Solution Approach 2:
The patent replaces complex mechanical killing systems with biological immune mechanisms. Instead of using external agents to directly kill cells, the system harnesses the natural T cell-mediated cytotoxicity, substituting a complex engineered killing mechanism with a sophisticated but natural immune response
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.